Research Article
EMMPRIN Expression in Oral Squamous Cell Carcinomas: Correlation with Tumor Proliferation and Patient Survival
Table 2
Univariable analysis of cancer-specific and recurrence-free survivals (at 3-years of follow-up).
| Factor | | Dead | Cancer-specific survival | value | | Recurrence | Recurrence-free survival | value |
| Gender | | | | | | | | | Female | 19 | 10 | 52.1 | 0.265 | 15 | 11 | 33.3 | 0.013 | Male | 55 | 23 | 57.8 | 47 | 20 | 50.7 | Age | | | | | | | | | <62 yrs | 37 | 19 | 46.4 | 0.324 | 29 | 16 | 37.7 | 0.546 | ≥62 yrs | 37 | 14 | 65.2 | 33 | 15 | 54.1 | Location | | | | | | | | | Lip | 7 | 1 | 83.3 | 0.491 | 7 | 1 | 83.3 | 0.383 | Tongue | 10 | 5 | 70 | 10 | 8 | 20 | Floor of the mouth | 24 | 10 | 61.3 | 20 | 8 | 63.3 | Gingiva | 5 | 2 | 60 | 4 | 2 | 50 | Retromolar trigone | 11 | 6 | 30.7 | 8 | 4 | 37.5 | Hard palate | 9 | 4 | 53.3 | 7 | 4 | 42.9 | Buccal mucosa | 8 | 5 | 37.5 | 6 | 4 | 33.3 | Tumor size | | | | | | | | | T1 | 13 | 1 | 88.9 | <0.001 | 13 | 4 | 83.3 | 0.009 | T2 | 29 | 9 | 70.4 | 28 | 12 | 53.4 | T3 | 9 | 5 | 30.5 | 8 | 5 | 30 | T4 | 23 | 18 | 16.9 | 13 | 10 | 23.1 | N status | | | | | | | | | 0 | 41 | 11 | 76.9 | 0.003 | 37 | 13 | 63.5 | 0.006 | 1 | 12 | 7 | 17.8 | 10 | 7 | 18 | 2 | 17 | 13 | 24.2 | 13 | 10 | 15.4 | 3 | 4 | 2 | 50 | 2 | 1 | 50 | Stage | | | | | | | | | I | 12 | 1 | 88.9 | <0.001 | 12 | 4 | 71.6 | 0.009 | II | 23 | 6 | 77.4 | 22 | 8 | 60 | III | 10 | 5 | 33.3 | 9 | 5 | 34.6 | IV | 29 | 21 | 26.9 | 19 | 14 | 23.7 | Tumor grade | | | | | | | | | G1 | 42 | 13 | 67.8 | 0.037 | 36 | 15 | 55.7 | 0.195 | G2/G3 | 32 | 20 | 42.1 | 26 | 16 | 35.3 | Treatment modality | | | | | | | | | SG | 28 | 28 | 76.2 | 0.050 | 26 | 10 | 55.2 | 0.134 | SG + RT | 23 | 23 | 47.7 | 21 | 13 | 32.8 | CT + SG or RCT | 23 | 23 | 37.8 | 15 | 8 | 50 | Margin status* | | | | | | | | | Free of tumor | 33 | 9 | 79.7 | 0.157 | 31 | 9 | 68.4 | 0.003 | With tumor | 24 | 11 | 50.1 | 23 | 16 | 26.1 | Perineural permeation | | | | | | | | | Absent | 66 | 28 | 58.2 | 0.243 | 54 | 25 | 49.8 | 0.041 | Present | 8 | 5 | 37.5 | 8 | 6 | 25 | Lymphatic invasion | | | | | | | | | Absent | 58 | 27 | 55.1 | 0.849 | 47 | 24 | 46.5 | 0.824 | Present | 16 | 6 | 61.1 | 15 | 7 | 53.3 | EMMPRIN expression | | | | | | | | | 0, 1+, 2+ | 18 | 3 | 88.5 | 0.011 | 17 | 8 | 58.8 | 0.882 | 3+ (overexpression) | 58 | 30 | 45.7 | 45 | 23 | 43.3 | EMMPRIN distribution | | | | | | | | | Homogeneous | 45 | 18 | 59.2 | 0.503 | 37 | 18 | 50.5 | 0.898 | Heterogeneous (periphery) | 29 | 15 | 50.7 | 25 | 13 | 39.6 | EMMPRIN fibroblasts | | | | | | | | | Absent | 9 | 6 | 20.8 | 0.092 | 8 | 6 | 18.8 | 0.088 | Present | 65 | 27 | 60.1 | 54 | 25 | 50.6 | Ki-67 | | | | | | | | | <50% (low expression) | 36 | 12 | 69.4 | 0.111 | 32 | 14 | 56.2 | 0.560 | ≥50% (high expression) | 38 | 11 | 45 | 30 | 17 | 39.7 |
|
|
SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy. Not determined in the 17 cases.
|